J. L. Bainbridge & Co., Inc. Biogen Inc. Transaction History
J. L. Bainbridge & Co., Inc.
- $1 Billion
- Q2 2024
A detailed history of J. L. Bainbridge & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, J. L. Bainbridge & Co., Inc. holds 60,604 shares of BIIB stock, worth $11.8 Million. This represents 1.4% of its overall portfolio holdings.
Number of Shares
60,604
Previous 50,018
21.16%
Holding current value
$11.8 Million
Previous $10.8 Million
30.26%
% of portfolio
1.4%
Previous 1.14%
Shares
2 transactions
Others Institutions Holding BIIB
# of Institutions
1,050Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.23 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$3.18 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.83 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.38 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$1.11 Billion0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $28B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...